International Journal of Clinical Oncology

, Volume 24, Issue 6, pp 614–623 | Cite as

Efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of gastric cancer: a meta-analysis of randomized controlled trials

  • Gongchen Wang
  • Binfeng Yang
  • Zhaoyuan Fu
  • Xin Wang
  • Zhiming ZhangEmail author
Review Article



Cisplatin played an important role in the treatment of gastric cancer (GC). Oxaliplatin has been shown to be at least as effective as cisplatin for GC, with less toxicity and a better tolerability profile. We performed a meta-analysis to compare the efficacy and safety of oxaliplatin-based regimen versus cisplatin-based regimen in the treatment of GC.


Databases of CNKI, CBM, VIP, Wanfang, PubMed, Embase, Cochrane Library were searched for eligible literatures from their establishments to November 2018. Randomized controlled trials that compared the efficacy and safety of oxaliplatin-based regimen with that of cisplatin-based regimen in the treatment of GC were included. Statistical analyses were calculated using RevMan 5.3 software.


Seven randomized controlled trials including 2297 patients were included. Compared with cisplatin-based regimen intervention in GC, oxaliplatin-based regimen treatment was able to significantly improve the partial response rate (OR = 1.26, 95% CI 1.07–1.49; p = 0.007), disease progression rate (OR = 0.41, 95% CI 0.25–0.66; p = 0.0002) and 1-year survival (OR = 1.25, 95% CI 1.00–1.56; p = 0.05). The toxicities of hematopoietic system were significantly higher in cisplatin-based regimen group (OR = 0.6, 95% CI 0.46–0.79; p = 0.0002), while oxaliplatin-based regimen group had higher neurosensory toxicity (OR = 2.21, 95% CI 1.52–3.21; p < 0.0001), In addition, gastrointestinal toxicity was similar between the two groups (OR = 1.01, 95% CI 0.5–2.01; p = 0.27).


Compared with cisplatin-based regimen, oxaliplatin-based regimen treatment has an obvious advantage in patients with GC with acceptable tolerance.


Gastric cancer Oxaliplatin Cisplatin Chemotherapy 



This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare that they had no conflict of interest in preparing this article.


  1. 1.
    Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917. CrossRefGoogle Scholar
  2. 2.
    Jemal A, Center MM, DeSantis C et al (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 19(8):1893–1907.
  3. 3.
    Hartgrink HH, Jansen EP, van Grieken NC et al (2009) Gastric cancer. Lancet 374(9688):477–490. CrossRefGoogle Scholar
  4. 4.
    Wilke H, Preusser P, Fink U et al (1989) Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 7(9):1318–1326. CrossRefGoogle Scholar
  5. 5.
    Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321. CrossRefGoogle Scholar
  6. 6.
    Paoletti X, Oba K, Burzykowski T et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303(17):1729–1737. CrossRefGoogle Scholar
  7. 7.
    Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2):163–168CrossRefGoogle Scholar
  8. 8.
    Yasui H, Tsurita G, Imai K (2014) DNA synthesis inhibitors for the treatment of gastrointestinal cancer. Expert Opin Pharmacotherap 15(16):2361–2372. CrossRefGoogle Scholar
  9. 9.
    Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215–221. CrossRefGoogle Scholar
  10. 10.
    Popov I, Radosevic-Jelic L, Jezdic S et al (2008) Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J BUON 13(4):505–511Google Scholar
  11. 11.
    Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141–148. CrossRefGoogle Scholar
  12. 12.
    Furlan AD, Pennick V, Bombardier C, et al (2009) 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine 34(18):1929–1941. CrossRefGoogle Scholar
  13. 13.
    Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181. CrossRefGoogle Scholar
  14. 14.
    Lefebvre C, Glanville J, Wieland LS et al (2013) Methodological developments in searching for studies for systematic reviews: past, present and future? Syst Rev 2:78. CrossRefGoogle Scholar
  15. 15.
    Kim YS, Sym SJ, Park SH et al (2014) A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer. Cancer Chemother Pharmacol 73(1):163–169. CrossRefGoogle Scholar
  16. 16.
    Al-Batran SE, Hartmann JT, Probst S et al (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 26(9):1435–1442. CrossRefGoogle Scholar
  17. 17.
    Cunningham DSN, Rao S, Iveson T et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. New Engl J Med 358(18):36–46. CrossRefGoogle Scholar
  18. 18.
    Jianqun L, Yungen Z (2014) clinical study of oxaliplatin combined with 5-fluorouracil and calcium folinate for chemotherapy in patients with advanced gastric cancer. Clin Med Eng 21(11):1447–1448Google Scholar
  19. 19.
    Wenyi W, yang X (2008) Clinical observation of cisplatin, oxaliplatin and paclitaxel in the treatment of advanced gastric cancer. Chin J Coal Ind Med 11(11):1726–1727Google Scholar
  20. 20.
    Machover D, Diaz-Rubio E, de Gramont A et al (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann oncol 7(1):95–98CrossRefGoogle Scholar
  21. 21.
    Kouroussis C, Souglakos J, Kakolyris S et al (2001) Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61(1):36–41. CrossRefGoogle Scholar
  22. 22.
    Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211. CrossRefGoogle Scholar
  23. 23.
    Argyriou AA, Polychronopoulos P, Iconomou G et al (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377. CrossRefGoogle Scholar
  24. 24.
    Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 350(23):2343–2351. CrossRefGoogle Scholar
  25. 25.
    Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 24(3):394–400. CrossRefGoogle Scholar
  26. 26.
    Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16):3478–3483. CrossRefGoogle Scholar
  27. 27.
    Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10(12 Pt 1):4055–4061. CrossRefGoogle Scholar
  28. 28.
    Nagamatsu M, Nickander KK, Schmelzer JD et al (1995) Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 18(8):1160–1167CrossRefGoogle Scholar
  29. 29.
    Nickander KK, McPhee BR, Low PA et al (1996) Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 21(5):631–639CrossRefGoogle Scholar
  30. 30.
    Gedlicka C, Scheithauer W, Schull B et al (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359–3361. CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Affiliated Hospital of Gansu University of Chinese MedicineLanzhouChina

Personalised recommendations